{"transactions":[{"id":4630146,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":32858,"kind":"person","name":"Casale Donn","position":1,"cik":"0002135296","reported_name":"Casale Donn","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-10-05T20:24:47.000Z","date":"2026-10-01","kind":"grant","planned":false,"acquired":true,"shares":1036923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on July 7, 2027, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":1036923,"derivative":{"exercise_price":4.12,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1036923},"source":{"system":"sec-edgar","filing":"0002135296-26-000009","document":"form4-10052026_081042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2135296/000213529626000009/form4-10052026_081042.xml","form_type":"4"}},{"id":1044,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":884,"kind":"person","name":"Smith Margaret Ekins","position":1,"cik":"0002149973","reported_name":"Smith Margaret Ekins","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-02T21:27:24.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":1001738,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on August 17, 2027, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":1001738,"derivative":{"exercise_price":5.77,"expiration_date":"2036-08-31","underlying":"Common Stock","underlying_shares":1001738},"source":{"system":"sec-edgar","filing":"0002149973-26-000004","document":"form4-09022026_090920.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2149973/000214997326000004/form4-09022026_090920.xml","form_type":"4"}},{"id":717950,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":32858,"kind":"person","name":"Casale Donn","position":1,"cik":"0002135296","reported_name":"Casale Donn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T20:30:21.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":898456,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on June 1, 2027, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":898456,"derivative":{"exercise_price":7.96,"expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":898456},"source":{"system":"sec-edgar","filing":"0002135296-26-000007","document":"form4-07022026_040714.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000213529626000007/form4-07022026_040714.xml","form_type":"4"}},{"id":725478,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-26T20:52:11.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and\nMr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock\nreceived upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001231919-26-000704","document":"form4-06262026_080605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000123191926000704/form4-06262026_080605.xml","form_type":"4"}},{"id":725477,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:19:23.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-285521","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526285521/ownership.xml","form_type":"4"}},{"id":725476,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35144,"kind":"person","name":"Shah Pratik","position":1,"cik":"0001580787","reported_name":"Shah Pratik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:20.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001580787-26-000004","document":"form4-06262026_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000158078726000004/form4-06262026_040614.xml","form_type":"4"}},{"id":725475,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:18.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001952533-26-000002","document":"form4-06262026_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195253326000002/form4-06262026_040612.xml","form_type":"4"}},{"id":725474,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:16.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001575408-26-000002","document":"form4-06262026_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000157540826000002/form4-06262026_040610.xml","form_type":"4"}},{"id":725473,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:15.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001357522-26-000005","document":"form4-06262026_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000135752226000005/form4-06262026_040608.xml","form_type":"4"}},{"id":725472,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:11.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001268854-26-000002","document":"form4-06262026_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000126885426000002/form4-06262026_040607.xml","form_type":"4"}},{"id":725471,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35141,"kind":"person","name":"SCHNEIDER PHILLIP M","position":1,"cik":"0001230051","reported_name":"SCHNEIDER PHILLIP M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:10.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001230051-26-000002","document":"form4-06262026_040604.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000123005126000002/form4-06262026_040604.xml","form_type":"4"}},{"id":725470,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-26T20:15:08.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":10.54,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001551891-26-000002","document":"form4-06262026_040601.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000155189126000002/form4-06262026_040601.xml","form_type":"4"}},{"id":739810,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":519588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":739809,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":25000,"price":10,"value":250000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025."}],"balance_after":12176,"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":739808,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2026-06-13T00:06:14.000Z","date":"2026-06-12","kind":"exercise","planned":true,"acquired":true,"shares":25000,"price":1.5,"value":37500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025."}],"balance_after":37176,"source":{"system":"sec-edgar","filing":"0001951287-26-000004","document":"form4-06132026_120610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000004/form4-06132026_120610.xml","form_type":"4"}},{"id":739806,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-13T00:04:44.000Z","date":"2026-06-12","kind":"sale","planned":true,"acquired":false,"shares":3355,"price":10,"value":33550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,907 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (the \"ESPP\") on June 30, 2025 and 1,745 shares acquired under the ESPP on December 31, 2025."}],"balance_after":90910,"source":{"system":"sec-edgar","filing":"0001398595-26-000004","document":"form4-06132026_120640.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000139859526000004/form4-06132026_120640.xml","form_type":"4"}},{"id":951494,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:27:42.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001794284-26-000002","document":"form4-01052026_090134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000179428426000002/form4-01052026_090134.xml","form_type":"4"}},{"id":951495,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:26:31.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001951287-26-000002","document":"form4-01052026_090126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195128726000002/form4-01052026_090126.xml","form_type":"4"}},{"id":951493,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:25:06.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001398595-26-000002","document":"form4-01052026_090101.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000139859526000002/form4-01052026_090101.xml","form_type":"4"}},{"id":951492,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:23:25.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001380762-26-000002","document":"form4-01052026_090119.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076226000002/form4-01052026_090119.xml","form_type":"4"}},{"id":951491,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:22:18.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001951238-26-000003","document":"form4-01052026_090113.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123826000003/form4-01052026_090113.xml","form_type":"4"}},{"id":951488,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:20:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":875000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":875000},"source":{"system":"sec-edgar","filing":"0001951291-26-000002","document":"form4-01052026_090152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195129126000002/form4-01052026_090152.xml","form_type":"4"}},{"id":951487,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:20:57.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001951291-26-000002","document":"form4-01052026_090152.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195129126000002/form4-01052026_090152.xml","form_type":"4"}},{"id":951490,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-05T21:19:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001378550-26-000003","document":"form4-01052026_090159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000137855026000003/form4-01052026_090159.xml","form_type":"4"}},{"id":951489,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:19:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":875000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":875000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":875000},"source":{"system":"sec-edgar","filing":"0001378550-26-000003","document":"form4-01052026_090159.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000137855026000003/form4-01052026_090159.xml","form_type":"4"}},{"id":998891,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":false,"shares":21828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":0.64,"expiration_date":"2028-11-28","underlying":"Common Stock","underlying_shares":21828},"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":998890,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"sale","planned":false,"acquired":false,"shares":21828,"price":8.7067,"value":190049.8476,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":10789,"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":998889,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:43:38.000Z","date":"2025-11-13","kind":"exercise","planned":false,"acquired":true,"shares":21828,"price":0.64,"value":13969.92,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025."}],"balance_after":32617,"source":{"system":"sec-edgar","filing":"0001380762-25-000005","document":"form4-11142025_111134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000138076225000005/form4-11142025_111134.xml","form_type":"4"}},{"id":998887,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"exercise","planned":false,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":89047,"derivative":{"exercise_price":0.84,"expiration_date":"2029-07-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998886,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"sale","planned":false,"acquired":false,"shares":136380,"price":8.8634,"value":1208790.492,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $8.8634, and the range of prices was between $8.62 and $9.04. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998885,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"sale","planned":false,"acquired":false,"shares":30000,"price":8.9119,"value":267357.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $8.9119, and the range of prices was between $8.87 and $8.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided."}],"balance_after":136380,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998884,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2025-11-14T23:42:54.000Z","date":"2025-11-12","kind":"exercise","planned":false,"acquired":true,"shares":30000,"price":0.84,"value":25200.0,"ownership":{"direct":true},"balance_after":166380,"source":{"system":"sec-edgar","filing":"0001951238-25-000005","document":"form4-11142025_111150.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000195123825000005/form4-11142025_111150.xml","form_type":"4"}},{"id":998882,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35144,"kind":"person","name":"Shah Pratik","position":1,"cik":"0001580787","reported_name":"Shah Pratik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T23:41:51.000Z","date":"2025-11-12","kind":"gift","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Pratik Shah Living Trust dated June 15, 2011"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction involved the transfer of shares to a charitable fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of The Pratik Shah Living Trust dated June 15, 2011."}],"balance_after":4474554,"source":{"system":"sec-edgar","filing":"0001580787-25-000004","document":"form4-11142025_111147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000158078725000004/form4-11142025_111147.xml","form_type":"4"}},{"id":998881,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35144,"kind":"person","name":"Shah Pratik","position":1,"cik":"0001580787","reported_name":"Shah Pratik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-14T23:41:51.000Z","date":"2025-11-12","kind":"gift","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By The Pratik Shah Living Trust dated June 15, 2011"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction involved the gift of shares to a trust in which the Reporting Person is not the trustee and the Reporting Person has no pecuniary interest over shares held in the trust."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is the trustee of The Pratik Shah Living Trust dated June 15, 2011."}],"balance_after":4574554,"source":{"system":"sec-edgar","filing":"0001580787-25-000004","document":"form4-11142025_111147.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000158078725000004/form4-11142025_111147.xml","form_type":"4"}},{"id":1057827,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2025-08-22T20:30:16.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":14.4869,"value":724345.0,"ownership":{"direct":false,"nature":"By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.4869 and the range of prices were between $14.31 and $14.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is trustee of the trust."}],"balance_after":1196494,"source":{"system":"sec-edgar","filing":"0001415889-25-022761","document":"form4-08222025_040804.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022761/form4-08222025_040804.xml","form_type":"4"}},{"id":1057830,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":739830,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1057829,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":15,"value":187500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025."}],"balance_after":10042,"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1057828,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":1.5,"value":18750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":22542,"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1059283,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-21T21:36:49.000Z","date":"2025-08-20","kind":"sale","planned":true,"acquired":false,"shares":37656,"price":14.0914,"value":530625.7584,"ownership":{"direct":false,"nature":"By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $14.0914 and the range of prices were between $14.00 and $14.205.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is trustee of the trust."}],"balance_after":1247447,"source":{"system":"sec-edgar","filing":"0001415889-25-022638","document":"form4-08212025_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022638/form4-08212025_090845.xml","form_type":"4"}},{"id":1059282,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2025-08-21T21:36:49.000Z","date":"2025-08-19","kind":"sale","planned":true,"acquired":false,"shares":12344,"price":14.0254,"value":173129.5376,"ownership":{"direct":false,"nature":"By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.0254 and the range of prices were between $14.00 and $14.08.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is trustee of the trust."}],"balance_after":1285103,"source":{"system":"sec-edgar","filing":"0001415889-25-022638","document":"form4-08212025_090845.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022638/form4-08212025_090845.xml","form_type":"4"}},{"id":1092380,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":544588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1092379,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16.9907,"value":254860.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average sale price for the transaction reported was $16.9907, and the range of prices were between $16.71 and $17.31. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":10315,"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1092378,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-07-03T20:21:24.000Z","date":"2025-07-01","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.5,"value":22500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,619 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":25315,"source":{"system":"sec-edgar","filing":"0001415889-25-019321","document":"form4-07032025_080720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925019321/form4-07032025_080720.xml","form_type":"4"}},{"id":1098456,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":4,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":6,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-01T20:42:51.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":370074,"price":18.46,"value":6831566.04,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund IV, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.20 to $18.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the \"Funds\"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4887254,"source":{"system":"sec-edgar","filing":"0001193805-25-000959","document":"e664668_4-arsp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525000959/e664668_4-arsp.xml","form_type":"4"}},{"id":1098455,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":29893,"kind":"person","name":"Flynn James E","position":1,"cik":"0001352546","reported_name":"Flynn James E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29894,"kind":"person","name":"DEERFIELD MANAGEMENT COMPANY, L.P.","position":2,"cik":"0001009258","reported_name":"DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39427,"kind":"organization","name":"Deerfield Mgmt III, L.P.","position":3,"cik":"0001610540","reported_name":"Deerfield Mgmt III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":39428,"kind":"organization","name":"Deerfield Private Design Fund III, L.P.","position":4,"cik":"0001603333","reported_name":"Deerfield Private Design Fund III, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29899,"kind":"person","name":"Deerfield Mgmt IV, L.P.","position":5,"cik":"0001713467","reported_name":"Deerfield Mgmt IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29900,"kind":"person","name":"Deerfield Private Design Fund IV, L.P.","position":6,"cik":"0001680307","reported_name":"Deerfield Private Design Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Class A Common Stock","published_at":"2025-07-01T20:42:51.000Z","date":"2025-06-27","kind":"sale","planned":false,"acquired":false,"shares":370075,"price":18.46,"value":6831584.5,"ownership":{"direct":false,"nature":"Through Deerfield Private Design Fund III, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.20 to $18.89, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the \"Reporting Persons\"). Deerfield Mgmt III, L.P. is the general partner of Deerfield Private Design Fund III, L.P. (\"Fund III\"). Deerfield Mgmt IV, L.P. is the general partner of Deerfield Private Design Fund IV, L.P. (collectively with Fund III, the \"Funds\"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P. and Deerfield Management Company, L.P."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."}],"balance_after":4887254,"source":{"system":"sec-edgar","filing":"0001193805-25-000959","document":"e664668_4-arsp.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1009258/000119380525000959/e664668_4-arsp.xml","form_type":"4"}},{"id":1100219,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":19524,"kind":"organization","name":"RA CAPITAL MANAGEMENT, L.P.","position":1,"cik":"0001346824","reported_name":"RA CAPITAL MANAGEMENT, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19525,"kind":"organization","name":"RA Capital Healthcare Fund LP","position":2,"cik":"0001315082","reported_name":"RA Capital Healthcare Fund LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":29189,"kind":"person","name":"RA Capital Nexus Fund II, L.P.","position":3,"cik":"0001825376","reported_name":"RA Capital Nexus Fund II, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":19526,"kind":"person","name":"Kolchinsky Peter","position":4,"cik":"0001384859","reported_name":"Kolchinsky Peter","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":19527,"kind":"person","name":"Shah Rajeev M.","position":5,"cik":"0001619841","reported_name":"Shah Rajeev M.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T21:21:48.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's board of directors, subject to Dr. Peter Kolchinsky's continuous service to the Issuer through the applicable vesting date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"RA Capital Management, L.P. (the \"Adviser\") is the investment manager for RA Capital Healthcare Fund, L.P. (the \"Fund\") and RA Capital Nexus Fund II, L.P. (the \"Nexus Fund II\"). The general partner of the Adviser is RA Capital Management GP, LLC (the \"Adviser GP\"), of which Dr. Peter Kolchinsky and\nMr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, the Nexus Fund II, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky 's arrangement with the Adviser, Dr. Kolchinsky holds the option for the benefit of the Fund and the Nexus Fund II. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or stock\nreceived upon exercise of the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018406","document":"form4-06272025_090643.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018406/form4-06272025_090643.xml","form_type":"4"}},{"id":1100218,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35145,"kind":"person","name":"Dadoo Rajeev","position":1,"cik":"0001951685","reported_name":"Dadoo Rajeev","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:43:08.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-090944","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017025090944/ownership.xml","form_type":"4"}},{"id":1100217,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35144,"kind":"person","name":"Shah Pratik","position":1,"cik":"0001580787","reported_name":"Shah Pratik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:23.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018386","document":"form4-06272025_040610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018386/form4-06272025_040610.xml","form_type":"4"}},{"id":1100216,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35143,"kind":"person","name":"Kelly Michael","position":1,"cik":"0001952533","reported_name":"Kelly Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:19.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018388","document":"form4-06272025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018388/form4-06272025_040614.xml","form_type":"4"}},{"id":1100215,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35142,"kind":"person","name":"Islam Saqib","position":1,"cik":"0001575408","reported_name":"Islam Saqib","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:18.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018385","document":"form4-06272025_040608.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018385/form4-06272025_040608.xml","form_type":"4"}},{"id":1100214,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":31257,"kind":"person","name":"Thompson Peter A.","position":1,"cik":"0001357522","reported_name":"Thompson Peter A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:15.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI, LP."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018387","document":"form4-06272025_040612.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018387/form4-06272025_040612.xml","form_type":"4"}},{"id":1100213,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:13.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018384","document":"form4-06272025_040607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018384/form4-06272025_040607.xml","form_type":"4"}},{"id":1100211,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35141,"kind":"person","name":"SCHNEIDER PHILLIP M","position":1,"cik":"0001230051","reported_name":"SCHNEIDER PHILLIP M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:10.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018383","document":"form4-06272025_040605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018383/form4-06272025_040605.xml","form_type":"4"}},{"id":1100212,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-27T20:30:06.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest in full on the earlier of June 25, 2026 or the date of the Issuer's 2026 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":17.26,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001415889-25-018382","document":"form4-06272025_040603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925018382/form4-06272025_040603.xml","form_type":"4"}},{"id":1105016,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"exercise","planned":true,"acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":559588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1105015,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"sale","planned":true,"acquired":false,"shares":15000,"price":16,"value":240000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":7696,"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1105014,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-20T22:38:45.000Z","date":"2025-06-18","kind":"exercise","planned":true,"acquired":true,"shares":15000,"price":1.5,"value":22500.0,"ownership":{"direct":true},"balance_after":22696,"source":{"system":"sec-edgar","filing":"0001415889-25-017901","document":"form4-06202025_100641.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925017901/form4-06202025_100641.xml","form_type":"4"}},{"id":1137197,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T21:00:13.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vested on January 1, 2025, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":200000,"derivative":{"exercise_price":5.58,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-25-014186","document":"form4-05222025_050505.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014186/form4-05222025_050505.xml","form_type":"4"}},{"id":1137196,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:13.000Z","date":"2025-05-20","kind":"sale","planned":false,"acquired":false,"shares":102969,"price":14.0966,"value":1451512.8054,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.0966 and the range of prices were between $14.02 and $14.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":89613,"source":{"system":"sec-edgar","filing":"0001415889-25-014186","document":"form4-05222025_050505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014186/form4-05222025_050505.xml","form_type":"4"}},{"id":1137195,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:13.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":100000,"price":5.58,"value":558000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 3,355 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":192582,"source":{"system":"sec-edgar","filing":"0001415889-25-014186","document":"form4-05222025_050505.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014186/form4-05222025_050505.xml","form_type":"4"}},{"id":1137194,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Immediately exercisable."}],"balance_after":470950,"derivative":{"exercise_price":1.01,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1137193,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"sale","planned":false,"acquired":false,"shares":120000,"price":14.2502,"value":1710024.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average sale price for the transaction reported was $14.2502 and the range of prices were between $14.25 and $14.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1137192,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":11572,"kind":"person","name":"SAUNDERS BRENT L","position":1,"cik":"0001268854","reported_name":"SAUNDERS BRENT L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T21:00:11.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":120000,"price":1.01,"value":121200.0,"ownership":{"direct":true},"balance_after":120000,"source":{"system":"sec-edgar","filing":"0001415889-25-014185","document":"form4-05222025_050503.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014185/form4-05222025_050503.xml","form_type":"4"}},{"id":1137191,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":752330,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1137190,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":14.1033,"value":705165.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7424,"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1137189,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":1.5,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":57424,"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1175617,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-08T20:45:04.000Z","date":"2025-04-07","kind":"exercise","planned":true,"acquired":false,"shares":27493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":24062,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":27493},"source":{"system":"sec-edgar","filing":"0001415889-25-010395","document":"form4-04082025_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925010395/form4-04082025_040401.xml","form_type":"4"}},{"id":1175616,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-08T20:45:04.000Z","date":"2025-04-07","kind":"exercise","planned":true,"acquired":false,"shares":22509,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":51555,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":22509},"source":{"system":"sec-edgar","filing":"0001415889-25-010395","document":"form4-04082025_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925010395/form4-04082025_040401.xml","form_type":"4"}},{"id":1175615,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:45:04.000Z","date":"2025-04-07","kind":"sale","planned":true,"acquired":false,"shares":50002,"price":12.301,"value":615074.602,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.301 and the range of prices were between $12.0063 and $12.64. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":210346,"source":{"system":"sec-edgar","filing":"0001415889-25-010395","document":"form4-04082025_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925010395/form4-04082025_040401.xml","form_type":"4"}},{"id":1175614,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:45:04.000Z","date":"2025-04-07","kind":"exercise","planned":true,"acquired":true,"shares":27493,"price":4.85,"value":133341.05,"ownership":{"direct":true},"balance_after":260348,"source":{"system":"sec-edgar","filing":"0001415889-25-010395","document":"form4-04082025_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925010395/form4-04082025_040401.xml","form_type":"4"}},{"id":1175613,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-08T20:45:04.000Z","date":"2025-04-07","kind":"exercise","planned":true,"acquired":true,"shares":22509,"price":4.85,"value":109168.65,"ownership":{"direct":true},"balance_after":232855,"source":{"system":"sec-edgar","filing":"0001415889-25-010395","document":"form4-04082025_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925010395/form4-04082025_040401.xml","form_type":"4"}},{"id":1194650,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":574588,"derivative":{"exercise_price":1.5,"expiration_date":"2032-05-23","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1194649,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":14,"value":140000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2024."}],"balance_after":7696,"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1194648,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-03-21T22:30:14.000Z","date":"2025-03-20","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,003 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":17696,"source":{"system":"sec-edgar","filing":"0001415889-25-008796","document":"form4-03212025_060301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925008796/form4-03212025_060301.xml","form_type":"4"}},{"id":1217410,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-06","kind":"exercise","planned":true,"acquired":false,"shares":49600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":74064,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":49600},"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1217409,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-05","kind":"exercise","planned":true,"acquired":false,"shares":400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":123664,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":400},"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1217408,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-06","kind":"sale","planned":true,"acquired":false,"shares":49600,"price":11.2106,"value":556045.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.2106 and the range of prices were between $11.00 and $11.55. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":210346,"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1217407,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-06","kind":"exercise","planned":true,"acquired":true,"shares":49600,"price":4.85,"value":240560.0,"ownership":{"direct":true},"balance_after":259946,"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1217406,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":400,"price":11,"value":4400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024."}],"balance_after":210346,"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1217405,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-03-07T22:12:15.000Z","date":"2025-03-05","kind":"exercise","planned":true,"acquired":true,"shares":400,"price":4.85,"value":1940.0,"ownership":{"direct":true},"balance_after":210746,"source":{"system":"sec-edgar","filing":"0001415889-25-007438","document":"form4-03072025_100311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925007438/form4-03072025_100311.xml","form_type":"4"}},{"id":1284847,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:06.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":false,"shares":40936,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":124064,"derivative":{"exercise_price":4.85,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":40936},"source":{"system":"sec-edgar","filing":"0001415889-25-002955","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925002955/form4-02042025_040201.xml","form_type":"4"}},{"id":1284846,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:35:06.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":false,"shares":9064,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.15,"expiration_date":"2032-05-01","underlying":"Common Stock","underlying_shares":9064},"source":{"system":"sec-edgar","filing":"0001415889-25-002955","document":"form4-02042025_040201.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925002955/form4-02042025_040201.xml","form_type":"4"}},{"id":1284845,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:06.000Z","date":"2025-02-03","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":12.3113,"value":615565.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $12.3113 and the range of prices were between $11.9732 and $12.76. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":210346,"source":{"system":"sec-edgar","filing":"0001415889-25-002955","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925002955/form4-02042025_040201.xml","form_type":"4"}},{"id":1284844,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:06.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":true,"shares":40936,"price":4.85,"value":198539.6,"ownership":{"direct":true},"balance_after":260346,"source":{"system":"sec-edgar","filing":"0001415889-25-002955","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925002955/form4-02042025_040201.xml","form_type":"4"}},{"id":1284843,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:35:06.000Z","date":"2025-02-03","kind":"exercise","planned":true,"acquired":true,"shares":9064,"price":3.15,"value":28551.6,"ownership":{"direct":true},"balance_after":219410,"source":{"system":"sec-edgar","filing":"0001415889-25-002955","document":"form4-02042025_040201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925002955/form4-02042025_040201.xml","form_type":"4"}},{"id":1308059,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-07T23:24:27.000Z","date":"2025-01-06","kind":"exercise","planned":true,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":9064,"derivative":{"exercise_price":3.15,"expiration_date":"2032-05-01","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-001053","document":"form4-01072025_110124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925001053/form4-01072025_110124.xml","form_type":"4"}},{"id":1308058,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T23:24:27.000Z","date":"2025-01-06","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":11.1013,"value":555065.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 16, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.1013 and the range of prices were between $11.00 and $11.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":210346,"source":{"system":"sec-edgar","filing":"0001415889-25-001053","document":"form4-01072025_110124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925001053/form4-01072025_110124.xml","form_type":"4"}},{"id":1308057,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":35140,"kind":"person","name":"Shawver Laura","position":1,"cik":"0001551891","reported_name":"Shawver Laura","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-07T23:24:27.000Z","date":"2025-01-06","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":3.15,"value":157500.0,"ownership":{"direct":true},"balance_after":260346,"source":{"system":"sec-edgar","filing":"0001415889-25-001053","document":"form4-01072025_110124.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925001053/form4-01072025_110124.xml","form_type":"4"}},{"id":1314780,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38730,"kind":"person","name":"Fitzpatrick Alexander A","position":1,"cik":"0001398595","reported_name":"Fitzpatrick Alexander A","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:47.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":152300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":152300,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":152300},"source":{"system":"sec-edgar","filing":"0001415889-25-000463","document":"form4-01032025_040130.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000463/form4-01032025_040130.xml","form_type":"4"}},{"id":1314779,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70322,"kind":"person","name":"Dorsey Brian","position":1,"cik":"0001380762","reported_name":"Dorsey Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:44.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":261900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":261900,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":261900},"source":{"system":"sec-edgar","filing":"0001415889-25-000462","document":"form4-01032025_040128.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000462/form4-01032025_040128.xml","form_type":"4"}},{"id":1314778,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:30:43.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":767600,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":767600,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":767600},"source":{"system":"sec-edgar","filing":"0001415889-25-000466","document":"form4-01032025_040134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000466/form4-01032025_040134.xml","form_type":"4"}},{"id":1314777,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:43.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":261900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":261900,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":261900},"source":{"system":"sec-edgar","filing":"0001415889-25-000466","document":"form4-01032025_040134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000466/form4-01032025_040134.xml","form_type":"4"}},{"id":1314776,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-03T21:30:37.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":261900,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":261900,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":261900},"source":{"system":"sec-edgar","filing":"0001415889-25-000464","document":"form4-01032025_040132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000464/form4-01032025_040132.xml","form_type":"4"}},{"id":1314775,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:37.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":767600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":767600,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":767600},"source":{"system":"sec-edgar","filing":"0001415889-25-000464","document":"form4-01032025_040132.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000464/form4-01032025_040132.xml","form_type":"4"}},{"id":1314774,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70321,"kind":"person","name":"Chakma Justin","position":1,"cik":"0001951238","reported_name":"Chakma Justin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:36.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":274100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":274100,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":274100},"source":{"system":"sec-edgar","filing":"0001415889-25-000461","document":"form4-01032025_040126.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000461/form4-01032025_040126.xml","form_type":"4"}},{"id":1314773,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:33.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":176700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":176700,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":176700},"source":{"system":"sec-edgar","filing":"0001415889-25-000460","document":"form4-01032025_040124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000460/form4-01032025_040124.xml","form_type":"4"}},{"id":1314772,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":38732,"kind":"person","name":"Karas Eric","position":1,"cik":"0001951287","reported_name":"Karas Eric","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:31.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":152300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":152300,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":152300},"source":{"system":"sec-edgar","filing":"0001415889-25-000459","document":"form4-01032025_040122.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000459/form4-01032025_040122.xml","form_type":"4"}},{"id":1325405,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-12-19T21:20:06.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":11.6705,"value":583525.0,"ownership":{"direct":false,"nature":"By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $11.6705, and the range of prices were between $11.56 and $11.95.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held in trust for the benefit of the Reporting Person and her spouse.  The Reporting Person and her spouse are trustees of the trust."}],"balance_after":1098499,"source":{"system":"sec-edgar","filing":"0001415889-24-029852","document":"form4-12192024_041203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029852/form4-12192024_041203.xml","form_type":"4"}},{"id":1325404,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70319,"kind":"person","name":"Tanimoto Sarina","position":1,"cik":"0001951291","reported_name":"Tanimoto Sarina","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CHIEF MEDICAL OFFICER"}}],"security":"Common Stock","published_at":"2024-12-19T21:20:06.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":11.6715,"value":583575.0,"ownership":{"direct":false,"nature":"By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $11.6715 and the range of prices were between $11.56 and $11.95.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is trustee of the trust."}],"balance_after":1297447,"source":{"system":"sec-edgar","filing":"0001415889-24-029852","document":"form4-12192024_041203.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029852/form4-12192024_041203.xml","form_type":"4"}},{"id":1325403,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":70320,"kind":"person","name":"Lowenthal Richard E","position":1,"cik":"0001378550","reported_name":"Lowenthal Richard E","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"PRESIDENT AND CEO"}}],"security":"Common Stock","published_at":"2024-12-19T21:20:04.000Z","date":"2024-12-17","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":11.6705,"value":583525.0,"ownership":{"direct":false,"nature":"By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The weighted average sale price for the transaction reported was $11.6705, and the range of prices were between $11.56 and $11.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held in trust for the benefit of the Reporting Person and his spouse.  The Reporting Person and his spouse are trustees of the trust."}],"balance_after":1098499,"source":{"system":"sec-edgar","filing":"0001415889-24-029851","document":"form4-12192024_041201.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924029851/form4-12192024_041201.xml","form_type":"4"}}],"next_cursor":"2024-12-19T21:20:04.000000Z,1325403"}